Development of a Clinically Viable Heroin Vaccine.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the American Chemical Society

• Publication date

  2017-06-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jacs.7b03334PMID 28574716PMCID PMC5612493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.

  2018cited by this paper
• Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

  2018cited by this paper
• Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant

  2017cited by this paper
• Influencing Antibody-Mediated Attenuation of Methamphetamine CNS Distribution through Vaccine Linker Design.

  2017cited by this paper
• An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life.

  2017cited by this paper
• Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

  2016cited by this paper
• Using Literal Text From the Death Certificate to Enhance Mortality Statistics: Characterizing Drug Involvement in Deaths.

  2016cited by this paper
• Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs.

  2016cited by this paper
• Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys

  2015cited by this paper
• A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity.

  2015cited by this paper
• Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.

  2015cited by this paper
• Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.

  2015cited by this paper
• Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

  2015cited by this paper
• Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine.

  2014cited by this paper
• Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates.

  2014cited by this paper
• Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.

  2014cited by this paper
• Fate of Systemically Administered Cocaine in Nonhuman Primates Treated with the dAd5GNE Anticocaine Vaccine

  2014cited by this paper
• Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy

  2014cited by this paper
• Investigating Hapten Clustering as a Strategy to Enhance Vaccines against Drugs of Abuse

  2014cited by this paper
• Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.

  2014cited by this paper
• Dynamic vaccine blocks relapse to compulsive intake of heroin

  2013cited by this paper
• Adenovirus Capsid-Based Anti-Cocaine Vaccine Prevents Cocaine from Binding to the Nonhuman Primate CNS Dopamine Transporter

  2013cited by this paper
• Selective Effects of a Morphine Conjugate Vaccine on Heroin and Metabolite Distribution and Heroin-Induced Behaviors in Rats

  2013cited by this paper
• Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

  2013cited by this paper
• Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice

  2013cited by this paper
• Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010.

  2013cited by this paper
• Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects

  2013cited by this paper
• A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.

  2013cited by this paper
• High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.

  2012cited by this paper
• Novel Cocaine Vaccine Linked to a Disrupted Adenovirus Gene Transfer Vector Blocks Cocaine Psychostimulant and Reinforcing Effects

  2012cited by this paper
• Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance.

  2012cited by this paper
• An Oxycodone Conjugate Vaccine Elicits Drug-Specific Antibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate Analgesia

  2012cited by this paper
• A vaccine strategy that induces protective immunity against heroin.

  2011cited by this paper
• A novel mechanism for glycoconjugate vaccine activation of the adaptive immune system

  2011cited by this paper
• Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.

  2010cited by this paper
• Antinociceptive Interactions between Mu-Opioid Receptor Agonists and the Serotonin Uptake Inhibitor Clomipramine in Rhesus Monkeys: Role of Mu Agonist Efficacy

  2010cited by this paper
• Antinociceptive interactions between mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of mu agonist efficacy

  2010cited by this paper
• Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

  2010cited by this paper
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

  2010cited by this paper
• Vaccines against morphine/heroine and its use as effective medication for preventing relapse to opiate addictive behaviors

  2009cited by this paper
• Increased Locomotor Activity Induced by Heroin in Mice: Pharmacokinetic Demonstration of Heroin Acting as a Prodrug for the Mediator 6-Monoacetylmorphine in Vivo

  2009cited by this paper
• Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.

  2009cited by this paper
• Opioid complications and side effects.

  2008cited by this paper
• Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

  2008cited by this paper
• Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility.

  2008cited by this paper
• Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use

  2008cited by this paper
• A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial

  2008cited by this paper
• Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

  2007cited by this paper
• Prescription naloxone: a novel approach to heroin overdose prevention.

  2007cited by this paper
• Prescription opioid abuse among enrollees into methadone maintenance treatment.

  2007cited by this paper
• Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin

  2006cited by this paper
• Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

  2006cited by this paper
• Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.

  2006cited by this paper
• Choice between Heroin and Food in Nondependent and Heroin-Dependent Rhesus Monkeys: Effects of Naloxone, Buprenorphine, and Methadone

  2006cited by this paper
• Prescribing Naloxone to Actively Injecting Heroin Users

  2006cited by this paper
• Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

  2006cited by this paper
• Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine

  2006cited by this paper
• Vaccine pharmacotherapy for the treatment of cocaine dependence.

  2005cited by this paper
• CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study

  2004cited by this paper
• Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems

  2004cited by this paper
• Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine.

  2003cited by this paper
• Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.

  2003cited by this paper
• Human therapeutic cocaine vaccine: safety and immunogenicity.

  2002cited by this paper
• Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys.

  2002cited by this paper
• Depot naltrexone: long-lasting antagonism of the effects of heroin in humans

  2002cited by this paper
• Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses.

  2002cited by this paper
• mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine.

  2001cited by this paper
• The economic costs of heroin addiction in the United States.

  2001cited by this paper
• The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long‐term retrospective cohort study

  2001cited by this paper
• Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs1 2

  2001cited by this paper
• Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1

  2000cited by this paper
• Self-administration of cocaine-heroin combinations by rhesus monkeys: antagonism by naltrexone.

  1998cited by this paper
• CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

  1998cited by this paper
• Active immunization alters the plasma nicotine concentration in rats.

  1997cited by this paper
• Efficacy of a therapeutic cocaine vaccine in rodent models

  1996cited by this paper
• Suppression of psychoactive effects of cocaine by active immunization

  1995cited by this paper
• A brief history of opiates, opioid peptides, and opioid receptors.

  1993cited by this paper
• Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.

  1993cited by this paper
• Lapse, Relapse and Survival among Opiate Addicts after Treatment

  1989cited by this paper
• Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

  1985cited by this paper
• A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine

  1984cited by this paper
• Carrier-priming leads to hapten-specific suppression

  1980cited by this paper
• Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin.

  1975cited by this paper
• Changes in heroin self-administration by a rhesus monkey after morphine immunisation

  1974cited by this paper
• Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

  1973cited by this paper
• Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection

  1972cited by this paper
• THE ENZYMATIC DEACETYLATION OF HEROIN AND RELATED MORPHINE DERIVATIVES BY BLOOD SERUM

  1941cited by this paper

• Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl

  2025cites this paper
• The Addictive Process of Opioids: Current and Novel Interventions in Opioid Use Disorder.

  2025cites this paper
• The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention

  2025cites this paper
• IFN-γ and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine.

  2025cites this paper
• An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.

  2025cites this paper
• Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights

  2025cites this paper
• Safety and Toxicology Profile of TT-6-AmHap Heroin Conjugate Vaccine

  2025cites this paper
• Synthesis and physicochemical characterization of new potential haptens and their precursors with morphine skeleton.

  2025cites this paper
• Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl

  2024cites this paper
• Opioid vaccine clinical testing: lessons learned

  2024cites this paper
• Vaccines as Immunotherapies for Substance Use Disorders.

  2024cites this paper
• Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl.

  2024cites this paper
• Evaluation of a hapten conjugate vaccine against the "zombie drug" xylazine.

  2024cites this paper
• Vaccines to Treat Substance Use Disorders: Current Status and Future Directions

  2024cites this paper
• Establishment of Broad-Specificity Monoclonal Antibody-Based Immunoassay for Rapid Detection of Indole-Type and Indazole-Type Synthetic Cannabinoids and Metabolites.

  2024cites this paper
• Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe institute for advanced study conference proceedings.

  2024cites this paper
• A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl

  2024cites this paper
• Opioid-Based Haptens: Development of Immunotherapy

  2024cites this paper
• Chemical tools for the opioids.

  2023cites this paper
• Biopharmaceuticals against substance use disorders - Present and future.

  2023cites this paper
• Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles.

  2023cites this paper
• A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice

  2023cites this paper
• Polyphosphazene: A New Adjuvant Platform for Cocaine Vaccine Development.

  2022cites this paper
• Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity

  2022cites this paper
• Design, Synthesis, and In Vivo Evaluation of C1-Linked 4,5-Epoxymorphinan Haptens for Heroin Vaccines

  2022cites this paper
• Immunotherapies for the Treatment of Drug Addiction

  2022cites this paper
• Tannic Acid, as a Structural Moiety Coupled to a Protein Antigen, Exhibiting a Molecular-Structure Adjuvant Activity for Antibody Specificity Enhancement.

  2022cites this paper
• Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin.

  2021cites this paper
• Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine.

  2021cites this paper
• The morphine/heroin vaccine decreased the heroin-induced antinociceptive and reinforcing effects in three inbred strains mouse.

  2021cites this paper
• The M_3-TT Vaccine Decreases the Antinociceptive Effects of Morphine and Heroin in Mice

  2021cites this paper
• Is it possible to design a clinically viable heroin vaccine? The progress and pitfalls

  2021cites this paper
• Medicinal Chemical Biology

  2021cites this paper
• Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine

  2021cites this paper
• An Evaluation of Diverse Therapeutic Interventions for Substance Use Disorders: Serotonergic Hallucinogens, Immunotherapy, and Transcranial Magnetic Stimulation

  2021cites this paper
• Morphine alkaloids: History, biology, and synthesis.

  2021cites this paper
• Recent Advances in the Treatment of Opioid Use Disorder

  2021cites this paper
• Vaccine design through transition state mimicry of heroin hydrolysis

  2021cites this paper
• Synthesis of 3‐O‐Carboxyalkyl Morphine Derivatives and Characterization of Their Acid‐Base Properties

  2021cites this paper
• Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats

  2020cites this paper
• Immunotherapy for treating methamphetamine, heroin and cocaine use disorders.

  2020cites this paper
• Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats.

  2020cites this paper
• Medications Development for Treatment of Opioid Use Disorder.

  2020cites this paper
• Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?

  2020cites this paper
• Designer drugs: a medicinal chemistry perspective (II)

  2020cites this paper
• Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity.

  2020cites this paper
• DARK Classics in Chemical Neuroscience: Heroin and Desomorphine.

  2020cites this paper
• Enhancement of a Heroin Vaccine Through Hapten Deuteration.

  2020cites this paper
• Sulfonate-isosteric replacement examined within heroin-hapten vaccine design.

  2020cites this paper
• Synthesis of Potential Haptens with Morphine Skeleton and Determination of Protonation Constants †

  2020cites this paper
• Emerging Concepts and Technologies in Vaccine Development

  2020cites this paper
• Anti-Opioid Antibodies in Individuals Using Chronic Opioid Therapy for Lower Back Pain.

  2020cites this paper
• Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice.

  2020cites this paper
• Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity.

  2020cites this paper
• Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability.

  2020cites this paper
• Broadly Neutralizing Synthetic Cannabinoid Vaccines

  2020cites this paper
• Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.

  2019cites this paper
• Prevention of Opioid Abuse and Treatment of Opioid Addiction : Current Status and Future Possibilities

  2019cites this paper
• Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders

  2019cites this paper
• The continuing search for an addiction vaccine.

  2019cites this paper
• Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

  2019cites this paper
• Vaccines against Drug Abuse: Morphine-Hapten Design and Synthesis

  2019cites this paper
• Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

  2019cites this paper
• Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

  2019cites this paper
• Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

  2019cites this paper
• Utilization of Cyclic Amides as Masked Aldehyde Equivalents in Reductive Amination Reactions.

  2019cites this paper
• A chemically contiguous hapten approach for a heroin–fentanyl vaccine

  2019cites this paper
• Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats

  2019cites this paper
• Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation.

  2019cites this paper
• Vaccine blunts fentanyl potency in male rhesus monkeys

  2019cites this paper
• Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone

  2019cites this paper
• Medications for Opioid Use Disorder Save Lives

  2019cites this paper
• Efficacious Vaccine against Heroin Contaminated with Fentanyl.

  2018cites this paper
• A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats

  2018cites this paper
• A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats

  2018cites this paper
• Challenges posed by novel vaccines in a hyperlinked society both to doctors and the health of their patients

  2018cites this paper
• Chemical Interventions for the Opioid Crisis: Key Advances and Remaining Challenges.

  2018cites this paper
• Effects of Conformational Changes in Peptide-CRM197 Conjugate Vaccines.

  2018cites this paper
• Biological Activity of the Carrier as a Factor in Immunogen Design for Haptens

  2018cites this paper
• Immunopharmacotherapies for Treating Opioid Use Disorder.

  2018cites this paper
• Twin epidemics: The surging rise of methamphetamine use in chronic opioid users.

  2018cites this paper
• Improved Admixture Vaccine of Fentanyl and Heroin Hapten Immunoconjugates: Antinociceptive Evaluation of Fentanyl-Contaminated Heroin

  2018cites this paper
• Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins.

  2018cites this paper
• Molecular Genetics and New Medication Strategies for Opioid Addiction.

  2018cites this paper
• Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats

  2018cites this paper
• Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

  2018cites this paper
• Tackling an Epidemic: New and Emerging Opioid Addiction Treatments Offer Hope for Solutions to This Crisis

  2018cites this paper
• A Vision for Vaccines: Combating the Opioid Epidemic.

  2017cites this paper
• Vaccines to combat the opioid crisis

  2017cites this paper
• A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse

  2017cites this paper
• Conjugate Vaccine Immunotherapy for Substance Use Disorder

  2017influential citation